HeartBeam (NASDAQ: BEAT), a medical technology company focused on advanced electrocardiogram solutions, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics, according to PatentVest’s “Total Cardiac Intelligence” report. The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, behind only GE Healthcare. This recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
The ranking underscores the rapid maturation of HeartBeam’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine's most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, and ischemia is a future goal.
HeartBeam is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement.
The full article detailing HeartBeam’s recognition can be viewed at https://ibn.fm/3ADRP. For more information about HeartBeam, visit www.HeartBeam.com. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
This achievement positions HeartBeam as a key player in the portable cardiac diagnostics market, with implications for expanding access to high-quality ECG monitoring outside traditional clinical settings. The recognition from PatentVest validates the company’s intellectual property strategy and technological advancements, which could accelerate adoption of its synthesis-ECG system among healthcare providers and patients. As HeartBeam continues to develop its platform, including future goals for ischemia detection, the company’s second-place ranking signals its potential to disrupt the cardiac monitoring landscape and improve outcomes for patients with arrhythmias.
